Viewing StudyNCT00100672

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
View Study With Definitions
Ignite Creation Date: 2024-05-05 @ 11:41 AM
Last Modification Date: 2024-10-26 @ 9:11 AM
Study NCT ID: NCT00100672
Status: COMPLETED
Last Update Posted: 2011-07-04
First Post: 2005-01-04
Brief Title: Study to Determine the Maximum Tolerated Dose of LErafAON in Patients With Advanced Cancer
Sponsor: INSYS Therapeutics Inc
Organization: INSYS Therapeutics Inc
Overview Dates Organization Conditions Design Enrollment Locations Outcomes

Conditions & Keywords Data

Conditions:
Name
Neoplasms
Keywords:
Name View
LErafAON-ETU View
Signal transduction View
Neoplasm View
Cancer View
NeoPharm View
Liposomes View
Antisense View
Anti-cancer View
Advanced neoplasm View
Advanced cancer View
Chemotherapy View
Refractory cancer View
Metastatic cancer View